Pirenzepine: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Pirenzepine == | |||
[[File:Pirenzepine.png|thumb|right|Chemical structure of Pirenzepine]] | |||
'''Pirenzepine''' is a [[muscarinic receptor]] antagonist that is primarily used in the treatment of [[peptic ulcer disease]]. It is a selective [[M1 receptor]] antagonist, which means it preferentially blocks the M1 subtype of muscarinic receptors. This selectivity is beneficial in reducing gastric acid secretion without significantly affecting other systems that are regulated by muscarinic receptors. | |||
Pirenzepine | |||
== | == Mechanism of Action == | ||
Pirenzepine works by inhibiting the action of [[acetylcholine]] on the M1 receptors located on [[parietal cells]] in the stomach. This inhibition leads to a decrease in the secretion of [[gastric acid]], which is a key factor in the development and exacerbation of peptic ulcers. By reducing acid secretion, pirenzepine helps in the healing of ulcers and provides symptomatic relief. | |||
== Clinical Uses == | |||
Pirenzepine is primarily used in the management of: | |||
* [[Peptic ulcer disease]] | * [[Peptic ulcer disease]] | ||
* [[ | * [[Gastritis]] | ||
It is not commonly used in the United States but has been used in other countries for its gastric acid-reducing properties. | |||
== Side Effects == | |||
[[ | The side effects of pirenzepine are generally mild due to its selectivity for M1 receptors. However, some patients may experience: | ||
[[ | |||
[[ | * [[Dry mouth]] | ||
* [[Constipation]] | |||
* [[Blurred vision]] | |||
These side effects are typical of anticholinergic agents but are less pronounced with pirenzepine compared to non-selective anticholinergics. | |||
== Pharmacokinetics == | |||
Pirenzepine is administered orally and is absorbed from the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The drug has a relatively long half-life, allowing for less frequent dosing compared to other anticholinergic agents. | |||
== Related Pages == | |||
* [[Muscarinic receptor]] | |||
* [[Peptic ulcer disease]] | |||
* [[Anticholinergic]] | |||
[[Category:Muscarinic antagonists]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 03:34, 13 February 2025
Pirenzepine[edit]
Pirenzepine is a muscarinic receptor antagonist that is primarily used in the treatment of peptic ulcer disease. It is a selective M1 receptor antagonist, which means it preferentially blocks the M1 subtype of muscarinic receptors. This selectivity is beneficial in reducing gastric acid secretion without significantly affecting other systems that are regulated by muscarinic receptors.
Mechanism of Action[edit]
Pirenzepine works by inhibiting the action of acetylcholine on the M1 receptors located on parietal cells in the stomach. This inhibition leads to a decrease in the secretion of gastric acid, which is a key factor in the development and exacerbation of peptic ulcers. By reducing acid secretion, pirenzepine helps in the healing of ulcers and provides symptomatic relief.
Clinical Uses[edit]
Pirenzepine is primarily used in the management of:
It is not commonly used in the United States but has been used in other countries for its gastric acid-reducing properties.
Side Effects[edit]
The side effects of pirenzepine are generally mild due to its selectivity for M1 receptors. However, some patients may experience:
These side effects are typical of anticholinergic agents but are less pronounced with pirenzepine compared to non-selective anticholinergics.
Pharmacokinetics[edit]
Pirenzepine is administered orally and is absorbed from the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The drug has a relatively long half-life, allowing for less frequent dosing compared to other anticholinergic agents.
